×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
MNOV – medicinova, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
MNOV
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/18
08:05 am
mnov
MediciNova (NASDAQ:MNOV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $9.00 price target on the stock.
Low
Report
MediciNova (NASDAQ:MNOV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $9.00 price target on the stock.
12/18
06:46 am
mnov
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy [Yahoo! Finance]
Low
Report
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy [Yahoo! Finance]
12/18
06:00 am
mnov
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
Low
Report
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
12/8
11:41 am
mnov
MediciNova (NASDAQ:MNOV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $9.00 price target on the stock.
Neutral
Report
MediciNova (NASDAQ:MNOV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $9.00 price target on the stock.
12/8
06:00 am
mnov
MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND
Medium
Report
MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND
12/1
06:00 pm
mnov
Message from the CEO to MediciNova Shareholders
Low
Report
Message from the CEO to MediciNova Shareholders
11/25
01:54 pm
mnov
MediciNova (NASDAQ:MNOV) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
MediciNova (NASDAQ:MNOV) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
11/18
06:57 am
mnov
MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor [Yahoo! Finance]
Neutral
Report
MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor [Yahoo! Finance]
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/12
04:35 pm
mnov
Form 10-Q MEDICINOVA INC For: Sep 30
Low
Report
Form 10-Q MEDICINOVA INC For: Sep 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/8
MediciNova Announces Plans to Initiate a Clinical Trial of MN-166 (ibudilast) for COVID-19 Acute Respiratory Distress Syndrome (ARDS)
37.8%
3/12 Form 4 MEDICINOVA INC For: Mar 12 Filed by: IWAKI YUICHI 30.2%
4/9 MediciNova, Inc. (NASDAQ: MNOV) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $11.00 price target on the stock. 26.1%
7/11 MediciNova Announces Phase 3 Clinical Trial Plan for MN-166 (ibudilast) in Progressive MS 14.5%
3/16 Form 4/A MEDICINOVA INC For: Mar 13 Filed by: Matsuda Kazuko 7.8%
4/23 Q1/2020 3/31/2020 EPS -0.060 ZacksConsensus -0.080 ActVsEst 0.020 - Beat 4.6%
8/23 Form 424B5 MEDICINOVA INC 3.8%
8/20 MediciNova: Leading The Pack In An MS Subtype [Seeking Alpha] 3.5%
5/7 MediciNova Participated in the RECEDE Phase 3 Degenerative Cervical Myelopathy Trial Kick-off Meeting, DCM Symposium and the Official Launch of Myelopathy.org in London, United Kingdom 3.1%
1/27 MediciNova Receives Notice of Intention to Grant for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in Europe 2.8%
3/12 Form 4 MEDICINOVA INC For: Mar 12 Filed by: IWAKI YUICHI 30.2%
4/9 MediciNova, Inc. (NASDAQ: MNOV) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $11.00 price target on the stock. 26.1%
7/11 MediciNova Announces Phase 3 Clinical Trial Plan for MN-166 (ibudilast) in Progressive MS 14.5%
3/16 Form 4/A MEDICINOVA INC For: Mar 13 Filed by: Matsuda Kazuko 7.8%
4/23 Q1/2020 3/31/2020 EPS -0.060 ZacksConsensus -0.080 ActVsEst 0.020 - Beat 4.6%
8/23 Form 424B5 MEDICINOVA INC 3.8%
8/20 MediciNova: Leading The Pack In An MS Subtype [Seeking Alpha] 3.5%
5/7 MediciNova Participated in the RECEDE Phase 3 Degenerative Cervical Myelopathy Trial Kick-off Meeting, DCM Symposium and the Official Launch of Myelopathy.org in London, United Kingdom 3.1%
1/27 MediciNova Receives Notice of Intention to Grant for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in Europe 2.8%
TOP News Decliners
10/24
Q3/2019 9/30/2019 EPS -0.050 ZacksConsensus -0.150 ActVsEst 0.100 - Beat
-12.8%
4/13 Form 4 MEDICINOVA INC For: Jul 13 Filed by: IWAKI YUICHI -6.7%
8/23 Form EFFECT MEDICINOVA INC -6.7%
3/9 MediciNova Announces Plans to Develop MN-166 (ibudilast) for Severe Pneumonia and Acute Respiratory Distress Syndrome (ARDS) -5.3%
2/17 MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Japan -5.2%
7/24 MediciNova Appoints Kazuko Matsuda to its Board of Directors -4.9%
4/20 MediciNova Receives Notice of Allowance for Second Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma -4.8%
8/9 Form S-3 MEDICINOVA INC -4.7%
4/16 Form 8-K MEDICINOVA INC For: Apr 15 -4.4%
9/30 MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in China -3.8%
4/13 Form 4 MEDICINOVA INC For: Jul 13 Filed by: IWAKI YUICHI -6.7%
8/23 Form EFFECT MEDICINOVA INC -6.7%
3/9 MediciNova Announces Plans to Develop MN-166 (ibudilast) for Severe Pneumonia and Acute Respiratory Distress Syndrome (ARDS) -5.3%
2/17 MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Japan -5.2%
7/24 MediciNova Appoints Kazuko Matsuda to its Board of Directors -4.9%
4/20 MediciNova Receives Notice of Allowance for Second Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma -4.8%
8/9 Form S-3 MEDICINOVA INC -4.7%
4/16 Form 8-K MEDICINOVA INC For: Apr 15 -4.4%
9/30 MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in China -3.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: